Lakewood-Amedex Biotherapeutics Redeems All Series C Preferred Stock for $1.27 Million
Lakewood-Amedex Biotherapeutics redeemed all 127,097 shares of its Series C Preferred Stock for $1.27 million, or $10 per share, from Shakawe Capital. The transaction was completed on November 4, 2026, with payment in cash, and the shares were canceled and returned to treasury.
How this was made
The 30-second read
Why it matters
The redemption eliminates a preferred equity claim, reducing dilution risk but also reflects a cash outflow of $1.27 million.
Market read
Limited relevance; primarily a corporate finance event for a micro‑cap biotech.
What to watch
Potential future financing needs after preferred stock removal
Background
Lakewood-Amedex Biotherapeutics filed an 8‑K reporting the redemption of its entire Series C preferred share class.
Market effects
minimal impact on biotech sector
none
none
Counterpoint
Redemption may signal cash constraints but could also clean balance sheet
Key entities
- companyLakewood-Amedex Biotherapeutics Inc.
Biotech firm completing a share redemption
- counterpartyShakawe Capital
Entity receiving the redemption proceeds
